Effects of propofol versus sevoflurane on cerebral oxygenation and cognitive outcome in patients with impaired cerebral oxygenation

Jun-ying Guo1,,*
Jie-yu Fang1,,*
San-rong Xu2
Ming Wei1
Wen-qi Huang1

1Department of Anesthesia, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong.
2Department of Anesthesia, Zhongshan Municipal Hospital of Fujian Province, Zhangzhou, Fujian, People's Republic of China.
*These authors contributed equally to this work.

Background: Postoperative neurocognitive dysfunction induced by anesthetics, particularly in elderly patients with impaired oxygenation, is a common complication of surgery and is eliciting increased interest in clinical practice. To investigate the effects of anesthetics on neurocognition, we compared the effects of propofol versus sevoflurane on cerebral oxygenation and cognitive outcome in patients with impaired cerebral oxygenation undergoing general anesthesia.

Methods: Sixty-three patients with impaired cerebral oxygenation (jugular venous bulb oxygen saturation [SjvO2] <50%) or cerebral blood flow/cerebral metabolic rate of oxygen ([CBF/CMRO2] ≤15%) undergoing elective abdominal surgery were randomly allocated into propofol group (group P) or sevoflurane group (group S). The clinical parameters and jugular venous bulb blood gas analysis were monitored throughout the surgical procedure. Cognitive function was assessed with the mini-mental state examination and Montreal Cognitive Assessment at day 1 and day 7 following surgery. S100β protein in plasma was measured using enzyme-linked immunosorbent assay.

Results: The SjvO2 increased during anesthesia induction and surgery when compared to baseline but had no significant difference between group P and group S. When compared to baseline, the CBF/CMRO2 was increased only at the end of surgery and extubation in group P; however, the CBF/CMRO2 in group S was increased during anesthesia induction at 1 hour, 2 hours, end of surgery, and extubation. Furthermore, the CBF/CMRO2 in group S was significantly higher than that in group P during anesthesia induction at 1 hour, 2 hours, and end of surgery. S100β protein did not significantly change at extubation and 1 day after surgery in both groups when compared to baseline. There was no significant difference in mini-mental state examination and Montreal Cognitive Assessment scores between group P and group S at all time points.

Conclusion: Sevoflurane showed similar effects in postoperative neurocognitive function as propofol but could improve cerebral oxygenation in patients with impaired cerebral oxygenation.

Keywords: saturation, postoperative cognitive dysfunction, propofol, sevoflurane

Introduction

Postoperative cognitive dysfunction (POCD) is a common complication following surgery.1,2 The incidence of POCD in the population undergoing noncardiac surgery has been reported to be as high as 9.1%–17% at day 7 following surgery.3,4 Increasing age has been reported to be associated with higher risk of POCD, and documented POCD lasting 3 months has been reported to be 12.7% in elderly patients who usually have preexisting impairment of cerebral oxygenation before surgery.5 These studies suggest that preexisting impairment of cerebral oxygenation may be a factor in deteriorating POCD; however, the mechanism is unclear.
A recent study in animals indicated that long-term administration of isoflurane, exceeding 4 hours, may induce cognitive impairment by reducing the \(N\)-methyl-\(D\)-aspartate receptor subunit NR2B and the phosphorylation of extracellular signal-regulated kinase 1/2.\(^6\) A previous clinical study also indicated that optimizing anesthetics and monitoring cerebral oxygenation could reduce POCD in older patients.\(^7\) These studies suggest that anesthetics may play a vital role in POCD by changing the cerebral oxygenation. Propofol and sevoflurane are commonly used anesthetics for sedation in general anesthesia, and their effects on POCD have raised the concerns of researchers. It was reported that, when compared to sevoflurane, higher dosage of propofol can further decrease cerebral blood flow (CBF),\(^8\) which has been, in combination with cerebral oxygen saturation, used to assess POCD in patients undergoing valvular heart surgery.\(^9\) However, whether propofol and sevoflurane affect intraoperative cerebral oxygenation and further affect postoperative outcomes in nonheart surgery patients is unknown. In this study, sevoflurane or propofol was applied to different patients with preexisting cerebral oxygenation impairment in order to investigate the effects of propofol and sevoflurane on the cerebral oxygenation during general anesthesia and the postoperative cognitive outcomes.

**Methods**

The experimental protocol was approved by the local research ethics committee (number 324, Sun Yat-sen University, 2012), and written informed consent was obtained from the patients. The inclusion criteria were physical status of I–III according to American Society of Anesthesiologists, age range of 40–75 years, presenting for elective abdominal surgery, and predicted surgery time ≥2 hours. Exclusion criteria were a history of cerebral vascular disease, preoperative cognitive dysfunction (illiterate group ≤17, primary and secondary school group ≤20, and junior high school and above group ≤24) assessed according to mini-mental state examination (MMSE), which is the most commonly used tool to screen cognitive function, language barriers, severe hearing, and visual impairment affecting cognitive function scores.

All patients (n=63) were administrated with jugular bulb catheterization and blood gas analysis was performed, including jugular venous bulb oxygen saturation (SjvO\(_2\)) and cerebral blood flow/cerebral metabolic rate of oxygen (CBF/CMRO\(_2\)). The SjvO\(_2\) was measured with blood gas analysis of blood samples from jugular venous bulb, CBF/CMRO\(_2\) was calculated by the equation:

\[
\text{CBF/CMRO}_2 = \frac{100}{(1.34 \times \text{Hb} \times (\text{SaO}_2 - \text{SjvO}_2)) + 0.003 \times (\text{Pao}_2 - \text{PjvO}_2)}
\]

(1)

Where Hb is hemoglobin, \(\text{SaO}_2\) is arterial oxygen saturation, \(\text{PaO}_2\) is arterial partial pressure oxygen, and \(\text{PjvO}_2\) is jugular venous partial pressure of oxygen.

Patients with decreased cerebral oxygenation (desaturation) defined as SjvO\(_2\) <50% were randomly allocated into propofol group (group P, n=32) or sevoflurane group (group S, n=31). In group P, propofol target-controlled infusion was applied for induction and programmed with the pharmacokinetic parameters of Marsh to a preset plasma concentration of propofol at 4.0 \(\mu\)g/mL. In group S, patients were sedated via volatile induction and maintenance technique (sevoflurane 2%–4% at end-tidal concentration) by tidal volume. When patients lost consciousness, fentanyl (3 \(\mu\)g/kg) and rocuronium (0.6 mg/kg) were administered before tracheal intubation. Anesthesia was maintained with propofol (2–3 \(\mu\)g/mL in plasma) and remifentanil (0.1–0.3 \(\mu\)g/kg/min) for group P, and sevoflurane (1%–3% of end-tidal concentration) inhalation and remifentanil (0.1–0.3 \(\mu\)g/kg/min) for group S, respectively. Propofol and sevoflurane were adjusted to keep Narcotrend value between 40 and 60. Fentanyl (1 \(\mu\)g/kg) was administrated in both groups.

Patients were mechanically ventilated to maintain the end-tidal carbon dioxide (\(\text{CO}_2\)) tension between 4.7 kPa and 5.5 kPa. Routine monitoring included invasive measurement of systemic blood pressure, heart rate, electrocardiogram, and pulse oxymetry. Blood samples in jugular venous bulb were taken at baseline, before anesthesia induction, after tracheal intubation, every hour during surgery, at the end of surgery, and at tracheal extubation for analysis of blood gas, oxygen saturation, and then calculation of CBF/CMRO\(_2\). The S100\(\beta\) protein was measured using enzyme-linked immunosorbent assay, according to the manufacturer’s instructions. The Montreal Cognitive Assessment (MoCA) and MMSE were used to assess the cognition of patients, according to the guidelines. Estimated blood loss and amount of fluid or blood administered during the surgery were also recorded.

**Trial registration**


**Statistical analysis**

Statistical analysis was performed using SPSS for Windows 19.0 (IBM Corporation, Armonk, NY, USA). Continuous
variables were presented as mean ± standard deviation [SD], and categorical variables were presented as frequency. Serial changes in cardiovascular SjvO₂ were analyzed using repeated measures analysis of variance. P<0.05 was considered to be statistically significant.

**Results**

**General information**

There was no significant difference between the two groups in general information, including age, gender, weight, and disease history (Table 1, all P>0.05). Furthermore, there was no significant difference in anesthesia time, surgical time, fluid infused during surgery, blood transfused, urine output, or blood loss between the two groups (Table 2, P>0.05). There was no significant difference in the administrated dosages of fentanyl, remifentanil, or morphine between the two groups (all P>0.05) except the dosage of norepinephrine, which was not used in group P (Table 2).

**Cognitive function**

As shown in Table 3, the MMSE scores at baseline and at day 1 and day 7 following surgery were similar and there was no significant difference at different time points between the two groups (P>0.05). Furthermore, the MMSE scores were not significantly different between group P and group S at all time points (all P>0.05). The MoCA scores displayed similar changes with MMSE, and there was no significant difference between the two groups at different time points (P>0.05; Table 3).

**SjvO₂ and CBF/CMRO₂**

In both group S and group P, the SjvO₂ increased during anesthesia induction at 1 hour, 2 hours, and the end of surgery. In group S, the SjvO₂ also increased at extubation. But there was no significant difference between group P and group S during anesthesia induction and surgery (Figure 1).

**Table 1** Characteristics of the patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Propofol group (n=32)</th>
<th>Sevoflurane group (n=31)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (M/F)</td>
<td>23/9</td>
<td>23/8</td>
<td>0.836</td>
</tr>
<tr>
<td>Age (years)</td>
<td>63.5±7.6</td>
<td>64.2±8.3</td>
<td>0.728</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>59.4±10.5</td>
<td>56.3±7.4</td>
<td>0.182</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>165±6</td>
<td>164±9</td>
<td>0.605</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3</td>
<td>5</td>
<td>0.421</td>
</tr>
<tr>
<td>Diabetes</td>
<td>0</td>
<td>1</td>
<td>0.306</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>1</td>
<td>3</td>
<td>0.286</td>
</tr>
<tr>
<td>ASA class II/III</td>
<td>30/2</td>
<td>25/6</td>
<td>0.118</td>
</tr>
</tbody>
</table>

*Note: Data presented as mean ± SD.*

**Abbreviations:** M, male; F, female; ASA, American Society of Anesthesiologists.

**Table 2** Surgical data in the two groups

<table>
<thead>
<tr>
<th></th>
<th>Propofol group (n=32)</th>
<th>Sevoflurane group (n=31)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anesthesia time (min)</td>
<td>277.6±177.5</td>
<td>289.7±106.6</td>
<td>0.545</td>
</tr>
<tr>
<td>Surgery time (min)</td>
<td>245.4±114.1</td>
<td>248.1±108.4</td>
<td>0.581</td>
</tr>
<tr>
<td>Blood loss (mL)</td>
<td>282.4±234.5</td>
<td>255.0±313.4</td>
<td>0.98</td>
</tr>
<tr>
<td>Fluid (mL)</td>
<td>2.873±1.001</td>
<td>3.250±1.177</td>
<td>0.33</td>
</tr>
<tr>
<td>Norepinephrine (µg)</td>
<td>0</td>
<td>272.5±366.7</td>
<td>0.0042</td>
</tr>
<tr>
<td>Fentanyl (mg)</td>
<td>0.49±0.15</td>
<td>0.46±0.13</td>
<td>0.6537</td>
</tr>
<tr>
<td>Morphine (mg)</td>
<td>36±7.91</td>
<td>37.8±6.51</td>
<td>0.8656</td>
</tr>
</tbody>
</table>

*Note: Data presented as mean ± SD.*

The CBF/CMRO₂ increased in group S during anesthesia induction at 1 hour, 2 hours, the end of surgery, and extubation, when compared to baseline. The CBF/CMRO₂ increased in group P at the end of surgery and extubation but did not change at the end of surgery, when compared to baseline. The CBF/CMRO₂ was significantly higher in group S than that in group P during anesthesia induction at 1 hour, 2 hours, and the end of surgery (Figure 2).

**S100β protein**

The level of S100β protein significantly increased at extubation and 1 day after surgery when compared to baseline in both groups (P<0.05). However, there was no significant difference in the levels of S100β protein between group P and group S at baseline, after extubation, and day 1 following surgery (P>0.05; Table 4).

**Discussion**

In this study, we compared the effects of propofol and sevoflurane on cerebral oxygenation and cognitive outcome in patients who underwent elective abdominal surgery. The results indicated that patients anesthetized with sevoflurane showed better cerebral oxygenation than those with propofol, and there was no significant difference in the SjvO₂ incidence of POCD, and S100β protein levels between group S and group P.

**Table 3** MMSE and MoCA scores in the two groups

<table>
<thead>
<tr>
<th>Test</th>
<th>Propofol group (n=32)</th>
<th>Sevoflurane group (n=31)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline MMSE</td>
<td>26.30±1.54</td>
<td>26.50±2.21</td>
<td>0.3948</td>
</tr>
<tr>
<td>MoCA</td>
<td>22.44±3.12</td>
<td>22.43±3.80</td>
<td>0.8814</td>
</tr>
<tr>
<td>Day 1 postsurgery MMSE</td>
<td>24.80±2.43</td>
<td>25.93±2.46</td>
<td>0.1767</td>
</tr>
<tr>
<td>MoCA</td>
<td>19.40±4.98</td>
<td>20.93±4.32</td>
<td>0.5086</td>
</tr>
<tr>
<td>Day 7 postsurgery MMSE</td>
<td>26.27±1.94</td>
<td>26.36±2.58</td>
<td>0.3400</td>
</tr>
<tr>
<td>MoCA</td>
<td>21.40±4.24</td>
<td>21.21±5.39</td>
<td>0.8107</td>
</tr>
</tbody>
</table>

*Note: Data presented as mean ± SD.*

*Abbreviations:* MMSE, mini-mental state examination; MoCA, Montreal Cognitive Assessment.
POCD is a common postoperative complication that may reduce the life quality of patients and increase mortality. It was reported that cerebral oxygen desaturation during thoracic surgery could predict early POCD, was observed in many surgeries, and may be associated with POCD, delirium, and longer hospitalization. Furthermore, the cerebral oxygen desaturation or impairment may be related to the administration of anesthetics. General anesthetic propofol has been reported to reduce CBF in equivalent proportion to cerebral metabolism, while sevoflurane can reduce cerebral metabolism but not as much as propofol. SjvO₂ is an indicator of global cerebral oxygen consumption and is independent of inhaled oxygen concentration during general anesthesia. It was reported that SjvO₂ remained unchanged during mild-to-moderate hemodilution, but was significantly lower under propofol anesthesia when compared with those under sevoflurane/nitrous oxide anesthesia. These studies are consistent with the results of the present study showing that SjvO₂ was increased at different time points. However, we did not find any significant difference between the two groups, suggesting that propofol and sevoflurane had similar effects on cerebral oxygen consumption.

Previous studies showed that, in total intravenous anesthesia with propofol–remifentanil, CBF decreased progressively with the decrease of cerebral electrical activity measured by bispectal index, while higher dose of sevoflurane increased the CBF despite a decrease in bispectral index value. These findings suggest the presence of an intrinsic dose-dependent vasodilatory effect of sevoflurane, which might have positive influence on patients with impaired baseline cerebral oxygenation. In the present study, the cerebral oxygenation was improved with significant increase in CBF/CMRO₂ following sevoflurane inhalation. In contrast, CBF/CMRO₂ only demonstrated a slight increase after intravenous anesthesia of propofol, suggesting that propofol has no significant influence on metabolic coupling, which was consistent with previous studies. However, it has been reported that, during carotid endarterectomy, propofol could be advantageous in cognitive function over sevoflurane, which is inconsistent with the present study showing that cognition was not significantly affected in both groups. This inconsistency remains to be further studied.

S100β is a 21 kDa calcium-binding protein primarily localized in astrocytes and associated with POCD as a neurodegenerative biomarker. A study in mice showed that propofol and isoflurane increased the level of S100β and neuronal apoptosis but had no significant effect on cognition. However, the present study found that both groups showed normal S100β level and cognitive functions, suggesting that propofol and sevoflurane, at the dosage used in the present study, had no significant effect on cognition in the

**Table 4 Changes in S100β protein levels in the two groups**

<table>
<thead>
<tr>
<th></th>
<th>Propofol group</th>
<th>Sevoflurane group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presurgery</td>
<td>505.57±169.95</td>
<td>502.38±149.35</td>
</tr>
<tr>
<td>Postsurgery***</td>
<td>630.56±126.47*</td>
<td>648.29±142.34*</td>
</tr>
<tr>
<td>Day 1 postsurgery</td>
<td>536.46±200.84</td>
<td>616.59±146.98</td>
</tr>
</tbody>
</table>

**Notes:** Data presented as mean ± SD. *P<0.05 versus presurgery. **immediately after tracheal extubation.
short term. Therefore, there is insufficient evidence to show that sevoflurane is better than propofol in those patients with impaired cerebral oxygenation. The comprehensive effects of general anesthetics such as propofol and sevoflurane on brain cells require further detailed studies.

**Conclusion**

The present study demonstrated that sevoflurane improved the cerebral oxygenation of patients with impaired cerebral oxygenation when compared to propofol and that both sevoflurane and propofol have no significant effect on postoperative neurocognitive function in the short term.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


**Therapeutics and Clinical Risk Management**

**Publish your work in this journal**

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.